3-chlorocarpipramine has been researched along with Basal Ganglia Diseases in 1 studies
3-chlorocarpipramine: RN given refers to parent cpd; structure
Basal Ganglia Diseases: Diseases of the BASAL GANGLIA including the PUTAMEN; GLOBUS PALLIDUS; claustrum; AMYGDALA; and CAUDATE NUCLEUS. DYSKINESIAS (most notably involuntary movements and alterations of the rate of movement) represent the primary clinical manifestations of these disorders. Common etiologies include CEREBROVASCULAR DISORDERS; NEURODEGENERATIVE DISEASES; and CRANIOCEREBRAL TRAUMA.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yamagami, S | 1 |
1 trial available for 3-chlorocarpipramine and Basal Ganglia Diseases
| Article | Year |
|---|---|
A crossover study of clocapramine and haloperidol in chronic schizophrenia.
Topics: Adult; Alanine Transaminase; Aspartate Aminotransferases; Basal Ganglia Diseases; Chronic Disease; D | 1985 |